Activity Description
In this third installment of a four-part educational series on Macular Telangiectasia Type 2 (MacTel), the discussion shifts from observation to intervention, exploring the neuroprotective therapeutic frontier. TFG’s expert consensus group examines the mechanism of action of ciliary neurotrophic factor (CNTF) and its role in preserving photoreceptors through Müller cell signaling and activation of cell survival pathways.
This video provides an in-depth overview of encapsulated cell therapy, including the NT-501 implant, which delivers sustained intraocular CNTF via genetically engineered retinal pigment epithelium cells housed in a semipermeable membrane. Clinical data demonstrating slowed ellipsoid zone loss are reviewed, and the consensus group emphasizes a central theme: The therapeutic goal is stabilization, not visual improvement. Patient selection, mechanism of action, and realistic outcome expectations in the era of neuroprotection are also discussed.
By the end of this episode, participants will understand how the shift to a neurodegenerative model has enabled disease-modifying intervention and what it means for long-term visual preservation.
The Fundingsland Group is accredited by the ACCME to provide continuing medical education for physicians.
Release Date: 4/30/26
Expiration Date: 4/30/27
Target Audience
This accredited educational activity is designed for ophthalmologists.
Grant Support Statement
This activity is supported by an unrestricted educational grant from Neurotech.
Faculty
